Clinical trial

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

NCT05191017

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2022-09-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2022-09-01Date precision: month

Registry last updated2022-08-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Prostatic Cancerunresolved

Cancer of Prostateunresolved

Cancer of the Prostateunresolved

Prostate Neoplasmunresolved

Castrate Resistant Prostate Cancerunresolved

Castration Resistant Prostatic Cancerunresolved

Castration Resistant Prostatic Neoplasmsunresolved

Interventions

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

Nuvation Bio Inc.lead sponsor

Mapped research locations

FairfaxVirginia, United States1 CantonOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05191017 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.